Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Outlook for the Non-Viral Gene Delivery Technologies Market Heading Into 2029?
The market size for non-viral gene delivery technologies has been fast expanding in recent years. The market value is projected to escalate from $3.96 billion in 2024 to $4.57 billion in 2025, with a compound annual growth rate (CAGR) of 15.6%. The significant growth seen in the historical period is thanks to the development of genetic research, an increase in chronic genetic disorders, the expansion of biotechnological and pharmaceutical R&D, enhancement in genetic and molecular biology studies, coupled with augmented governmental and institutional financial support.
Expectations suggest a swift expansion in the market size of non-viral gene delivery technologies in the upcoming years. The market worth is predicted to escalate to $8.06 billion by the year 2029, with a compound annual growth rate (CAGR) of 15.2%. This growth in the projected timeframe can be credited to the rising demand for customized medicine, an uptick in its application in cancer and rare disease research, emergence of clustered regularly interspaced short palindromic repeats and gene editing technologies, expedited growth in the field of mRNA-based treatments, and expansion in the realm of cell therapy and tissue engineering. The forthcoming period will witness specific trends like advances in lipid nanoparticles and polymer-based vectors, evolution of deoxyribonucleic acid and ribonucleic acid therapies, incorporation of artificial intelligence and computational modeling, introduction of next-generation lipid nanoparticles (LNPs), and progress in the field of nanotechnology.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=27367&type=smp
Which Factors Are Pushing The Non-Viral Gene Delivery Technologies Market Forward?
The growing desire for personalized medicine is set to fuel the expansion of the non-viral gene delivery technologies market. Personalized medicine is a tailored medical strategy that specifically designs prevention, diagnosis, and treatment regimes based on the unique genetic composition, lifestyle, and environmental aspects of an individual. This surge in demand for personalized medicine is spurred by developments in genomic sequencing technologies, which enable highly precise diagnosis, specifically aimed therapies and enhanced treatment outcomes, designed for individual patients. The increasing concentration on personalized medicine is promoting a heightened demand for non-viral gene delivery technologies, as they offer secure and more flexible methods to transport therapeutic genes customized to suit an individual’s genetic makeup, without the risks affiliated with viral vectors. For example, in February 2024, the Personalized Medicine Coalition, a non-profit organization based in the US reported that the Food and Drug Administration (FDA) sanctioned 16 innovative personalized therapies for patients suffering from rare diseases in 2023, in contrast to the 6 in 2022. Therefore, the escalating demand for personalized medicine is propelling the growth of the non-viral gene delivery technologies market.
Which Segment Held The Largest Share In The Non-Viral Gene Delivery Technologies Market In 2025?
The non-viral gene delivery technologies market covered in this report is segmented
1) By Product: Reagents And Kits, Delivery Devices, Pre-Formulated Nanoparticles
2) By Delivery: In-Vitro, In-Vivo, Ex-Vivo
3) By Technology: Electroporation, Lipid-Based Transfection, Polymer-Based Transfection, Physical Methods (Microinjection, Gene Gun), Nanoparticles
4) By Application: Gene Therapy, Deoxyribonucleic Acid (DNA) Vaccines, Ribonucleic Acid Interference (RNAi), Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Or Cas9 Gene Editing, Protein Expression
5) By End-Use: Biotechnology And Biopharmaceutical Companies, Research And Academic Institutes, Other End-Uses
Subsegments:
1) By Reagents And Kits: Transfection Reagents, Plasmid Deoxyribonucleic Acid (DNA) Kits, Messenger Ribonucleic Acid (RNA) Delivery Kits, Small Interfering Ribonucleic Acid (RNA) Delivery Kits, Clustered Regularly Interspaced Short Palindromic Repeats Associated Protein Reagents, Cell-Specific Delivery Reagents
2) By Delivery Devices: Electroporation Systems, Microinjection Systems, Gene Guns Or Biolistic Delivery Devices, Ultrasound-Mediated Delivery Devices, Hydrodynamic Gene Delivery Systems
3) By Pre-Formulated Nanoparticles: Lipid-Based Nanoparticles, Polymer-Based Nanoparticles, Gold-Based Nanoparticles, Dendrimer-Based Nanoparticles, Carbon Nanotube-Based Nanoparticles, Inorganic Compound-Based Nanoparticles
How Are Key Trends Driving Expansion In The Non-Viral Gene Delivery Technologies Industry?
Leading corporations in the non-viral gene delivery market are placing a high emphasis on the innovation of cutting-edge solutions like non-viral genetic medicine platforms. Such platforms enhance the safety and effectiveness of gene therapies by introducing therapeutic genes or nucleic acids into cells without viruses. This results in reduced immune reactions and safety concerns, while also allowing for precise gene therapy delivery for various diseases. For example, Generation Bio Co., a biotech firm based in the United States specializing in genetic medicine, unveiled its immune-quiet DNA (iqDNA) in October 2023. This innovative DNA is an advanced version of their closed-ended DNA (ceDNA) that avoids direct detection by the immune system, displaying cytokine levels and tolerability that is similar to chemically altered mRNA in both mice and non-human primates when administered through their lipid nanoparticle (LNP) system. Given iqDNA’s excellent tolerability, Generation Bio Co. is making it the prime DNA material in all its projects, including its lead hemophilia A initiative.
Which Organizations Are Driving Progress In The Non-Viral Gene Delivery Technologies Industry?
Major companies operating in the non-viral gene delivery technologies market are Thermo Fisher Scientific Inc., Danaher Corporation, Merck KGaA, Evonik Industries AG, Moderna Inc., Boehringer Ingelheim GmbH, Agilent Technologies Inc., Lonza Group AG, Sartorius AG, Bio-Rad Laboratories Inc., Bio-Techne Corp., Takara Bio Inc., GenScript Biotech Corporation, Poseida Therapeutics Inc., ElevateBio LLC, ProBio Inc., ReCode Therapeutics Inc., Altogen Biosystems Inc., Generation Bio, Indee Labs Inc.
Get The Full Report Here:
Which Region Is Expected To Experience The Highest Growth In The Non-Viral Gene Delivery Technologies Industry?
North America was the largest region in the non-viral gene delivery technologies market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the non-viral gene delivery technologies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=27367&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model